0001741830--12-312022Q3FALSE00017418302022-01-012022-09-3000017418302022-11-02xbrli:shares00017418302022-09-30is...
SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a...
Berenberg Bank analyst Zhiqiang Shu initiated coverage with a Buy rating on Kronos Bio (KRON - Research Report) today and set a price target of...
false12-312022Q2000174183000017418302022-01-012022-06-3000017418302022-07-29xbrli:shares UNITED STATES SECURITIES AND...
false12-312022Q1000174183000017418302022-01-012022-03-3100017418302022-04-27xbrli:shares UNITED STATES SECURITIES AND EXCHANGE...
SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a...
SAN MATEO, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to...
Kronos Bio et Invivoscribe s'associent pour un diagnostic complémentaire à utiliser avec...
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's...
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Kronos Bio (KRON - Research Report), with a price target...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the...
Company continuing to enroll patients in both Phase 3 registrational AGILITY trial of entospletinib and Phase...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.